I
Infliximab [Remsima]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Standard Drug List
Active ingredient: Infliximab
General information
Subsidy Information and Financing Scheme
Drug Guidance for Subsidy
13/09/2024 Intravenous infliximab biosimilars for treating inflammatory conditions
The Ministry of Health’s Drug Advisory Committee has recommended to:
Reclassify infliximab biosimilar (Remsima) 100 mg vial from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
List infliximab biosimilar (Ixifi) 100 mg vial on the SDL
in view of favourable cost effectiveness compared to other anti-tumour necrosis factor alfa (anti-TNFα) biologics at the prices proposed by the manufacturers.
Subsidy status
[R] SDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:
Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn’s disease;
Children aged 6 years or older with severe active Crohn’s disease; and
Children aged 6 years or older with moderately to severely active ulcerative colitis.
[NR] SDL subsidy does not apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.
13/09/2024 Subcutaneous infliximab biosimilar for treating inflammatory conditions
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended subcutaneous infliximab biosimilar (Remsima) for inclusion on the MOH List of Subsidised Drugs for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The decision was based on unacceptable pricing proposal from the company.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Remsima Infusion 100 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
* Clinical information is available for this product.
Subcutaneous
REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120 MG/ML IN PRE-FILLED PEN [SIN16070P]*
REMSIMA SOLUTION FOR SUBCUTANEOUS INJECTION 120 MG/ML IN PRE-FILLED SYRINGE [SIN16069P]*
* Clinical information is available for this product.